Clinical trials: Systemic Lupus, Skin Lupus
Lupus Nephritis, Remission
Trial of Belimumab Combined With Multi-target Induction Therapy in Lupus Nephritis
The goal of this single-center, prospective clinical trial is to test the safety and efficacy of belimumab combined with multi-target therapy in the treatment of severe lupus nephritis.
- Conditions
- Lupus Nephritis, Remission, Safety Issues
- Trial name
- BEAM (NCT05863936)
- Testing
- Methylprednisolone Injectable Suspension, Belimumab Injection, Immunosuppressive Agents
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Nanjing University School of Medicine
Systemic Lupus Erythematosus (SLE)
A Study of CAR-T Cells in Subjects With Systemic Lupus Erythematosus
The purpose of this study is to assess the safety and efficacy of CAR-T cell therapy in Subjects with SLE.
- Trial name
- NCT06900764
- Testing
- CAR-T cell
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Systemic Lupus Erythematosus
A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects
This will be the first-in-human study designed to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses of DS-7011a in healthy participants.
- Trial name
- NCT05203692
- Testing
- DS-7011a
- Where
- 2 sites in United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Daiichi Sankyo
Lupus Erythematosus, Systemic
Anti-ficolin-2 Autoantibodies in Lupus Nephritis
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the production of multiple autoantibodies. The prevalence and significance of antibodies against Ficolin-2 have not been yet investigated.
- Trial name
- Ficolupus2 (NCT03063281)
- Testing
- BIological analysis
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- University Hospital, Grenoble
Lupus Nephritis (LN), Immune Thrombocytopenia (ITP)
A Clinical Study of YTS109 Cell in R/R Systemic Lupus Erythematosus
This study evaluates the safety and efficacy of YTS109 cells in adults with refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus-Immune Thrombocytopenia (SLE-ITP).
- Trial name
- NCT06943937
- Testing
- YTS109 cell injection
- Where
- China
- Volunteers
- 2 people
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd.
Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)
A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
This Phase IIa, open-label, single-arm study includes an initial Safety Run-In followed by dose expansion to evaluate the safety, tolerability, cellular kinetics, pharmacodynamics, and preliminary clinical activity of a single…
- Trial name
- NCT07328581
- Testing
- ICG318, BCMA-CD19-IL-15/IL-15 sushi Compound CAR T following lymphodepletion
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- iCell Gene Therapeutics
Systemic Lupus Erythematosus
Web-based Genetic Research on Lupus
The goal of this new lupus research study is two-fold: first, to understand the genetic associations found between people's DNA and this disease, and second, to apply this understanding to drug development efforts with the…
- Trial name
- NCT02530944
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- 23andMe, Inc.
Lupus Nephritis, Diastolic Dysfunction
Diastolic Dysfunction and Inflammatory Biomarkers in Lupus Nephritis
This cross-sectional observational study aims to investigate the correlation between echocardiographic parameters of left ventricular diastolic dysfunction (E/A ratio, e', E/e' ratio, LAVI, and LVEF) and systemic inflammatory…
- Conditions
- Lupus Nephritis, Diastolic Dysfunction, Systemic Lupus Erythematosus, Heart Failure, Diastolic
- Trial name
- NCT07837544
- Volunteers
- 90 people
- Sponsor
- Assiut University
Lupus Nephritis
A Pilot Study for the Efficacy and Safety of Tacrolimus in the Treatment of Refractory Lupus Nephritis
The purpose of this protocol is to determine whether Tacrolimus and Prednisolone are effective and safe in the treatment of the cyclophosphamide-resistant, refractory diffuse proliferative lupus nephritis
- Trial name
- NCT00569101
- Testing
- tacrolimus
- Where
- South Korea
- Volunteers
- 9 people
- Sponsor
- Seoul National University Hospital
Systemic Lupus Erythematosus
Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care
This study will be conducted to assess the safety, tolerability, and immunogenicity of repeat doses of BOS161721 (20 milligrams [mg], 60 mg, and 120 mg) administered subcutaneously in adult participants with moderately to…
- Trial name
- NCT03371251
- Testing
- BOS161721
- Where
- 68 sites in United States, Argentina and 10 more
- Volunteers
- 143 people
- Sponsor
- Boston Pharmaceuticals
Systemic Lupus Erythematosus
O-GlcNAcylation Role in the Pathophysiology of Systemic Lupus Erythematosus
This study aims at defining the role of O-GlcNAcylation is in the physiopathology of systemic lupus erythematosus (SLE). O-GlcNAcylation is a metabolic pathway potentially implicated in SLE with potential for the discovery of new…
- Trial name
- METABOLUPS (NCT04440566)
- Testing
- blood sample
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Bordeaux
Systemic Lupus Erythematosus
Hormonal and Environmental Risk Factors for Developing Systemic Lupus Erythematosus: The Carolina Lupus (CLU) Study
Systemic lupus erythematosus (SLE) is severe, chronic, disabling autoimmune disease that significantly affects health status and quality of life.
- Trial name
- NCT00342095
- Where
- 6 sites in United States
- Volunteers
- 640 people, healthy volunteers welcome
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
Lupus Nephritis
RING - Rituximab for Lupus Nephritis With Remission as a Goal
OBJECTIVE To test whether Rituximab (RTX) is efficacious to achieve complete renal response (CR) in Lupus Nephritis (LN) patients with persistent proteinuria (≥1g/d) despite at least 6 months of standard of care (SOC).
- Trial name
- RING (NCT01673295)
- Testing
- RTX infusions, Standard of Care
- Where
- Belgium
- Volunteers
- 194 people
- Sponsor
- Frédéric A. Houssiau, MD, PhD
Lupus Nephritis
Zanubrutinib in Participants With Active Proliferative Lupus Nephritis
The primary objective of this study is to evaluate the efficacy of zanubrutinib added to standard of care as measured by complete renal response for participants with active proliferative lupus nephritis
- Trial name
- NCT04643470
- Testing
- Zanubrutinib
- Where
- 44 sites in China
- Volunteers
- 177 people
- Sponsor
- BeiGene
Lupus Erythematosus, Systemic
The Role of Lipids in Immune Cell Function in SLE Patients
The overall aim of this project is to investigate the different types of immune cells found in the blood of patients with Systemic Lupus Erythematosus (SLE) and healthy donors.
- Trial name
- NCT04361734
- Testing
- Blood sampling to include Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA)
- Where
- United Kingdom
- Volunteers
- 300 people
- Sponsor
- University College, London
Lupus Nephritis
Mesenchymal Stem Cell Transfusion for the Treatment of Refractory Lupus Nephritis
Lupus nephritis (LN) is the most common and serious complication of systemic lupus erythematosus (SLE), which can lead to permanent kidney injury and uremia.
- Trial name
- LN (NCT06485648)
- Testing
- Umbilical cord mesenchymal stem cells, Normal saline
- Volunteers
- 96 people
- Sponsor
- Chinese PLA General Hospital
System Lupus Erythematosus(SLE)
Anti-CD19 CAR-T Cell Therapy for Patients With Refractory Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by B-cell dysfunction leading to the production of autoantibodies that play a key role in the onset and progression of the disease.
- Trial name
- NCT07720310
- Testing
- CAR T cells chimeric antigen receptor cells
- Where
- Belarus
- Volunteers
- 12 people
- Sponsor
- N.N. Alexandrov National Cancer Centre
Lupus Nephritis
T Regulatory Cells IN LUPUS NEPHRITIS
To study the role FoxP3-positive T regulatory cells in the pathogenesis of Lupus Nephritis, and determine the factors associated with levels of T regs . To compare the functional capacity of T regs in LN and in normal individuals.
- Trial name
- NCT06428539
- Testing
- T-reg cells
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Assiut University
Lupus Erythematosus, Systemic
Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)
The purpose of this study is to evaluate the safety and efficacy of 3 different doses of belimumab, administered in addition to standard therapy, in patients with active SLE disease.
- Trial name
- NCT00071487
- Testing
- Belimumab 1 mg/kg, Belimumab 4 mg/kg, Belimumab 10 mg/kg
- Where
- 62 sites in United States, Canada
- Volunteers
- 449 people
- Sponsor
- Human Genome Sciences Inc.
Systemic Lupus Erythematosus
Exploratory Study of DHA in Systemic Lupus Erythematosus Patients
The primary objective of the study is to assess the efficacy of DHA in patients with SLE.
- Trial name
- NCT03396393
- Testing
- Dihydroartemisinin tablet
- Volunteers
- 120 people
- Sponsor
- Kunming Pharmaceuticals, Inc.